Forging the Future
GRIN-X is the intersection for Genetics, Robotics, Information and Nanotechnology.
Futurists predict that in the near decade GRIN will completely transform the market space.
Never before imagined products, therapies, technologies and markets will emerge.
Conventional regulations, traditional financing, and corporate models will be disrupted.
Via our corporate strategy and competitive intelligence services, we provide emerging technology pathfinders, key stake holders, and visionary investors, a road map to navigate the human and business terrain, to achieve successful emergence of new medicines, treatments and technology products.
Since 2014 every GRIN-X client exceeded goals. For example:
Cancer Prevention Pharmaceuticals - 2018
In April 2018, UK-based Mallinckrodt had exercised its option to the license agreement, and paid CPP $10 million to support the pivotal Phase 3 clinical trial of CPP-1X/sul in patients with the orphan disease familial adenomatous polyposis (FAP).
Calimmune - 2017
Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California and Sydney, Australia for an upfront payment of $91 million, with possible milestone payments reaching an eventual total of $416 million.
8987 E Tanque Verde Rd
Tucson, AZ 85749